一级预防抗栓的现状和未来.ppt

Antithombosis in Primary Prevention Where do we stand/where are we going Dr. Carlos Brotons;Primary prevention trials with Aspirin: review of the Evidence;Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using Aspirin;Aspirin in the primary prevention of cardiovascular (CV) events;Primary findings (total CV events) from the six key trials;Results of the Meta-analysis regarding the prevention of coronary heart disease;Bartolucci AA, et al. Am J Cardiol 2006;98:746–50.;Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men;32%;17%;24%;;Reduction in serious vascular events with antiplatelet therapy in high-risk patients287 studies, 135.000 patients;Reduction in serious vascular events with antiplatelet therapy in high-risk patients287 studies, 135.000 patients;Major CV events Relative risk reduction vs absolute risk reduction;Major CV events Relative risk reduction vs absolute risk reduction;Guidelines support the use of aspirin for primary prevention of CV events;European guidelines on CVD prevention in clinical practice;American Heart Association (AHA) Guidelines;AHA guidelines for CVD prevention in women (2007 update);Guide to clinical preventive services 2008: recommendations from USPSTF;Guide to clinical preventive services 2008: recommendations from USPSTF;Guide to clinical preventive services 2008: recommendations from USPSTF;Guide to clinical preventive services 2008: recommendations from USPSTF;Who should be treated with aspirin?;Antithombosis in Primary Prevention Where are we going ? Ongoing trials to assess the benefit:risk profile of low-dose aspirin in the prevention of first CV events;The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events);Rationale;CHD risk continuum;Overall CHD, Stroke, and CV Death ;Overview of the ARRIVE Trial;Study design;ARRIVE Trial: Inclusion Criteria;ARRIVE Trial: Primary efficacy endpoint;Summary of the ARRIVE Trial